Myasthenia Gravis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Clinical Trials
• Forums

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Condition:   Myasthenia Gravis Interventions:   Drug: HBM9161 Injection (680mg);   Drug: HBM9161 Drug Product (340mg) Sponsor:   Harbour BioMed (Guangzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Conditions:   Refractory Myasthenia Gravis;   Rituximab Intervention:   Drug: Rituximab Sponsor:   First Affiliated Hospital, Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2022 Category: Research Source Type: clinical trials